Skier dies in off-piste avalanche at Russian resort after sudden collapse
Skier dies in off-piste avalanche at Russian resort after sudden collapse
Skier dies in off-piste avalanche at Russian resort after sudden collapse
A 45-year-old man from St. Petersburg has died while skiing at the Igora Ski resort in Russia's Leningrad Region. The incident occurred on 29 January 2026, when Alexander Belousov was caught in an avalanche outside the marked slopes. Friends who were with him at the time saw the tragedy unfold.
Belousov fell ill while skiing near the resort's main lift. His condition quickly worsened, and despite the rapid arrival of emergency medical teams, doctors could not revive him. Preliminary findings indicate that cardiac complications may have caused his death.
Friends who witnessed the event described how he suddenly collapsed. Emergency responders and local police are now examining the exact circumstances surrounding the incident.
The group had been skiing off-piste when the avalanche struck, burying Belousov under the snow. Rescue efforts were immediate, but the severity of his condition left no chance for survival.
Authorities continue to investigate the causes of the tragedy. The incident has raised questions about safety measures for skiers venturing beyond designated areas. A full report on the findings is expected in the coming weeks.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?